CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Epoetin Alfa 40000 UNT/MLdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03822884
NCT03822884Phase 1Completed
CompareCT.gov

Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers

Bio Sidus SA·interventional·Posted Jan 30, 2019·Updated Feb 12, 2020

In Brief

A Phase 1 clinical trial evaluating Epoetin Alfa 40000 UNT/ML for Anemia. Completed, enrolled 24 participants.

Detailed Summary

Pharmacokinetic/Pharmacodynamic Study of 3 Epoetin Alfa Formulations in Single Subcutaneous Doses Administered to Healthy Volunteers SPONSOR Biosidus S.A.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 30, 2019
Enrollment StartSep 1, 2016
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 7.4 years ago

Interventions

Epoetin Alfa 40000 UNT/MLdrug

40.000 UI subcutaneous single dose